Biocytogen Pharmaceuticals has entered into a platform license agreement with Taisho Pharmaceutical, granting Taisho the right to access and use Biocytogen’s proprietary RenNano fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programmes.

Under the terms of the agreement, Taisho will leverage RenNano mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed.

“We are very pleased to enter into this collaboration with Taisho. RenNano is a robust and powerful fully human VHH discovery platform that provides an ideal antibody foundation for the development of a broad range of next-generation innovative therapeutics. Through this collaboration, RenNano will support Taisho’s internal R&D efforts and help establish a more efficient, fully human VHH discovery workflow,” said Dr Yuelei Shen, President and CEO, Biocytogen.

This collaboration further expands Biocytogen’s growing portfolio of global partnerships. Leveraging its robust in-vivo immune response, the RenNano platform enables the efficient generation of fully human heavy-chain-only antibodies with high diversity, specificity, affinity and favourable developability. The platform comprehensively supports next-generation VHH-based antibody modalities, including bi-specific antibodies, Antibody-Drug Conjugates (ADCs), and in vivo CAR-T therapies.